A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice

Kum, D. B.; Mishra, N.; Boudewijns, R.; Gladwyn-Ng, Ivan; Alfano, Christian; Ma, J.; Schmid, M. A.; Marques, R. E.; Schols, D.; Kaptein, S.; Nguyen, Laurent; Neyts, J.; Dallmeier, K.

doi:10.1038/s41541-018-0092-2

Article (Scientific journals)

A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice

Kum, D. B.; Mishra, N.; Boudewijns, R. et al.

2018 • In npj Vaccines, 3 (1)

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/243283

DOI
10.1038/s41541-018-0092-2

PubMed
30564463

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

NPJ Vaccines (2018) Kum.pdf

Publisher postprint (3.31 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Zika virus vaccine; Article; CD4+ T lymphocyte; CD8+ T lymphocyte; NMRI mouse; Zika fever; Zika virus

Abstract :

[en] The recent Zika virus (ZIKV) epidemic in the Americas led to an intense search for therapeutics and vaccines. Here we report the engineering of a chimeric virus vaccine candidate (YF-ZIKprM/E) by replacing the antigenic surface glycoproteins and the capsid anchor of YFV-17D with those of a prototypic Asian lineage ZIKV isolate. By intracellular passaging, a variant with adaptive mutations in the E protein was obtained. Unlike YFV-17D, YF-ZIKprM/E replicates poorly in mosquito cells. Also, YF-ZIKprM/E does not cause disease nor mortality in interferon α/β, and γ receptor KO AG129 mice nor following intracranial inoculation of BALB/c pups. A single dose as low as 1 × 10 2 PFU results, as early as 7 days post vaccination, in seroconversion to neutralizing antibodies and confers full protection in AG129 mice against stringent challenge with a lethal inoculum (10 5 LD 50 ) of either homologous or heterologous ZIKV strains. Induction of multi-functional CD4 + and CD8 + T cell responses against ZIKV structural and YFV-17D non-structural proteins indicates that cellular immunity may also contribute to protection. Vaccine immunogenicity and protection was confirmed in other mouse strains, including after temporal blockade of interferon-receptors in wild-type mice to facilitate ZIKV replication. Vaccination of wild-type NMRI dams with YF-ZIKprM/E results in complete protection of foetuses against brain infections and malformations following a stringent intraplacental challenge with an epidemic ZIKV strain. The particular characteristic of YF-ZIKprM/E in terms of efficacy and its marked attenuation in mice warrants further exploration as a vaccine candidate. © 2018, The Author(s).

Disciplines :

Microbiology

Author, co-author :

Kum, D. B.; KU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium

Mishra, N.; KU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium

Boudewijns, R.; KU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium

Gladwyn-Ng, Ivan ; GIGA-Neurosciences, Interdisciplinary Cluster for Applied Genoproteomics (GIGA-R), University of Liège, C.H.U. Sart Tilman, Liège, Belgium

Alfano, Christian ; Université de Liège - ULiège > Neurosciences-Molecular Regulation of Neurogenesis

Ma, J.; KU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium

Schmid, M. A.; KU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium

Marques, R. E.; Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, Sao Paulo, Brazil

Schols, D.; KU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium

Kaptein, S.; KU Leuven Department of Microbiology and Immunology, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium

More authors (3 more)

Language :

English

Title :

A yellow fever–Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice

Publication date :

2018

Journal title :

npj Vaccines

eISSN :

2059-0105

Publisher :

Nature Publishing Group

Volume :

Issue :

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 January 2020

Statistics

Number of views

99 (2 by ULiège)

Number of downloads

51 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Fauci, A. S. & Morens, D. M. Zika virus in the Americas—yet another arbovirus threat. N. Engl. J. Med. 374, 601–604 (2016)
Theiler, M. & Smith, H. H. The use of Yellow Fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65, 787–800 (1937)
Barrett, A. D. T. Yellow fever live attenuated vaccine: a very successful live attenuated vaccine but still we have problems controlling the disease. Vaccine 35, 5951–5955 (2017)
Seligman, S. J. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD). Vaccine 32, 5769–5775 (2014)
Chambers, T. J., Nestorowicz, A., Mason, P. W. & Rice, C. M. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73, 3095–3101 (1999)
Arroyo, J. et al. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J. Virol. 75, 934–942 (2001)
Guy, B. et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28, 632–649 (2010)
Dayan, G. H., Pugachev, K., Bevilacqua, J., Lang, J. & Monath, T. P. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses 5, 3048–3070 (2013)
Apte-Sengupta, S., Sirohi, D. & Kuhn, R. J. Coupling of replication and assembly in flaviviruses. Curr. Opin. Virol. 9, 134–142 (2014)
Amberg, S. M. & Rice, C. M. Mutagenesis of the NS2B-NS3-mediated cleavage site in the flavivirus capsid protein demonstrates a requirement for coordinated processing. J. Virol. 73, 8083–8094 (1999)
Amberg, S. M., Nestorowicz, A., McCourt, D. W. & Rice, C. M. NS2B-3 proteinase-mediated processing in the yellow fever virus structural region: in vitro and in vivo studies. J. Virol. 68, 3794–3802 (1994)
Lobigs, M. & Lee, E. Inefficient signalase cleavage promotes efficient nucleocapsid incorporation into budding flavivirus membranes. J. Virol. 78, 178–186 (2004)
Lobigs, M., Lee, E., Ng, M. L., Pavy, M. & Lobigs, P. A flavivirus signal peptide balances the catalytic activity of two proteases and thereby facilitates virus morphogenesis. Virology 401, 80–89 (2010)
Lee, E., Stocks, C. E., Amberg, S. M., Rice, C. M. & Lobigs, M. Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage In vitro is lethal for virus production. J. Virol. 74, 24–32 (2000)
Pletnev, A. G., Bray, M., Hanley, K. A., Speicher, J. & Elkins, R. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J. Virol. 75, 8259–8267 (2001)
Xie, X. et al. Understanding Zika virus stability and developing a chimeric vaccine through functional analysis. mBio 8, e02134–16 (2017)
Monath, T. P. et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 33, 62–72 (2015)
Yuan, L. et al. A single mutation in the prM protein of Zika virus contributes to fetal microcephaly. Science 358, 933–936 (2017)
Faria, N. R. et al. Zika virus in the Americas: early epidemiological and genetic findings. Science 352, 345–349 (2016)
Meier, K. C., Gardner, C. L., Khoretonenko, M. V., Klimstra, W. B. & Ryman, K. D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 5, e1000614 (2009)
Zmurko, J. et al. The viral polymerase inhibitor 7-deaza-2’-C-methyladenosine is a potent inhibitor of in vitro Zika Virus replication and delays disease progression in a robust mouse infection model. PLoS Negl. Trop. Dis. 10, e0004695 (2016)
Theys, K. et al. Zika genomics urgently need standardized and curated reference sequences. PLoS Pathog. 13, e1006528 (2017)
McElroy, K. L., Tsetsarkin, K. A., Vanlandingham, D. L. & Higgs, S. Role of the yellow fever virus structural protein genes in viral dissemination from the Aedes aegypti mosquito midgut. J. Gen. Virol. 87, 2993–3001 (2006)
van Boheemen, S. et al. Quasispecies composition and evolution of a typical Zika virus clinical isolate from Suriname. Sci. Rep. 7, 2368 (2017)
Grifoni, A. et al. Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. J. Virol. 90, 4771–4779 (2017)
James, E. A. et al. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J. Virol. 87, 12794–12804 (2013)
Guy, B. et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26, 5712–21 (2008)
Gladwyn-Ng, I. et al. Stress-induced unfolded protein response contributes to Zika virus-associated microcephaly. Nat. Neurosci. 21, 63–71 (2018)
Diamond, M. S. & Coyne, C. B. Vaccines in 2017: closing in on a Zika virus vaccine. Nat. Rev. Immunol. 18, 89–90 (2018)
To, A. et al. Recombinant Zika virus subunits are immunogenic and efficacious in mice. mSphere 3, pii: e00576–17 (2018)
Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017)
Espinosa, D. et al. Passive transfer of immune sera induced by a Zika virus-like particle vaccine protects AG129 mice against lethal Zika virus challenge. EBioMedicine 27, 61–70 (2018)
Salvo, M. A., Kingstad-Bakke, B., Salas-Quinchucua, C., Camacho, E. & Osorio, J. E. Zika virus like particles elicit protective antibodies in mice. PLoS Negl. Trop. Dis. 12, e0006210 (2018)
Sumathy, K. et al. Protective efficacy of Zika vaccine in AG129 mouse model. Sci. Rep. 7, 46375 (2017)
Xu, K. et al. Recombinant Chimpanzee adenovirus vaccine AdC7-M/E protects against Zika virus infection and testis damage. J. Virol. 92, e01722-17 (2018)
Shan, C. et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat. Med. 23, 763–767 (2017)
Li, X. F. et al. Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone. Nat. Commun. 9, 673 (2018)
Li, P. et al. Zika virus attenuation by codon pair deoptimization induces sterilizing immunity in mouse models. J. Virol. 92, e00701–18 (2018)
Shan, C. et al. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nat. Commun. 8, 676 (2017)
Guirakhoo, F. et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75, 7290–7304 (2001)
Op De Beeck, A. et al. Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope. J. Virol. 77, 813–820 (2003)
Op De Beeck, A., Rouillé, Y., Caron, M., Duvet, S. & Dubuisson, J. The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals. J. Virol. 78, 12591–12602 (2004)
Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48–53 (2016)
Giel-Moloney, M. et al. Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine. Sci. Rep. 8, 13206 (2018)
Widman, D. G. et al. A reverse genetics platform that spans the Zika virus family tree. mBio 8, e02014–16 (2017)
Lazear, H. M. et al. A mouse model of Zika virus pathogenesis. Cell. Host. Microbe 19, 720–730 (2016)
van der Most, R. G., Harrington, L. E., Giuggio, V., Mahar, P. L. & Ahmed, R. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 296, 117–124 (2002)